

The nomination committee's proposal for board of directors of ADDvise Group AB (publ)

To the annual general meeting (AGM) of ADDvise Group AB (publ) on 3 May 2024, the nomination committee has decided to propose re-election of Fredrik Celsing, Staffan Torstensson, Johanne Brændgaard and Anna Ljung as members of the board of directors. In addition, the nomination committee proposes election of Thomas Eklund. Erland Pontusson has declined re-election.

It is proposed that Staffan Torstensson is re-elected chairman of the board of directors.

Thomas Eklund has a master's degree in Economic and Business Administration from Stockholm School of Economics. Thomas Eklund has more than 20 years of experience from the life science industry as well as investment banking experience. Currently he is acting as an independent advisor to Investor / Patricia Industries and Impilo. Thomas Eklund is also serving as chairman of Immedica and Mabtech and member of the board of Boule, Surgical Science and Swedencare. Thomas Eklund is independent in relation to the company, its management, and its largest shareholders and holds 83,721 A-shares and 2,295,669 B-shares in the company.

A presentation of the current members of the board of directors is available on ADDvise Group's website.

The nomination committee's full proposals to the AGM 2024 will be published in connection with the notice to the AGM 2024.

The nomination committee of ADDvise Group for the AGM 2024 consists of:

- Per-Anders Tammerlöv (chairman of the nomination committee), representative of the shareholder Rikard Akhtarzand
- Per Åhlgren, representative of the shareholder Gomobile nu AB
- Roger Lindqvist, representative of the shareholder Caracal AB
- Staffan Torstensson, chairman of ADDvise Group

The members of the nomination committee jointly represent approximately 35 percent of the votes in the company as per June 30, 2023.

For further information, please contact:

Hanna Myhrman, General Counsel
+46 709 – 82 92 23
hanna.myhrman@addvisigroup.se

About ADDvise Group

ADDvise is an international life science group. Operating a decentralised ownership model, we develop and acquire high quality companies within the business areas Lab and Healthcare. The Group comprises more than 20 companies and generates annual revenues of close to SEK 2 billion. ADDvise is listed on Nasdaq First North Premier Growth Market. Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.